INVITED COMMENTARY
Manish Mehta, MD, MPH, Albany, NY I want to congratulate Dr Behzad Farivar and colleagues on a well-written manuscript that analyzes the National Surgical Quality Improvement Program (NSQIP) database and focuses attention on the implications of concomitant hypogastric artery embolization and endovascular repair of infrarenal aortoiliac aneurysms.
I read this manuscript with great interest and vividly recall when during my first year of vascular fellowship at Montefiore Medical Center in 1999, Dr Frank Veith asked me to analyze the implications of unilateral and bilateral hypogastric artery interruption during endovascular aneurysm repair (EVAR). At the time, the largest stent graft iliac limb diameter was 14 mm, which was designed to treat a 12-to 13-mm common iliac artery; there were only a handful of endovascular surgery programs across the United States, the operative experience in endovascular aortoiliac aneurysm repair was limited, simple unretractable coils were the only available embolic agents, and most patients with aortoiliac aneurysms underwent open surgical repair.
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One would think that by 2017, nearly two decades later, the evolution of techniques and technology, which includes flared iliac limbs, branched aortoiliac devices, and a variety of parallel stent graft configurations, would allow us to march beyond having a continuous debate on the implications of hypogastric artery interruption during EVAR; unfortunately not. The complexities of aortoiliac morphology and the persistent limitations in technology have led us to a crossroads where hypogastric artery interruption is still necessary in select patients with aortoiliac aneurysms.
In the early 2000s, when current techniques and technology were unavailable, unilateral and most often bilateral hypogastric artery interruption was sometimes considered necessary and performed in high-risk patients during EVAR. During this period, there were several fundamental lessons learned that allowed surgeons to limit the complications of hypogastric artery interruption, including ischemic colitis, significant pelvic ischemia, buttock claudication, and erectile dysfunction; these included (1) preservation of circumflex collateral branches from the external iliac and common femoral arteries, (2) interruption of the hypogastric artery at its origin and avoidance of distal embolization, (3) staging of bilateral hypogastric artery interruption, (4) evaluation of the mesenteric arteries (superior mesenteric artery and celiac) for stenosis, and (5) avoidance of excessive blood loss, hypotension, and shock.
3-9 What we learned is that if we followed these principles, unilateral and even bilateral hypogastric artery interruption was "relatively safe," particularly in patients who were at high risk for open surgical repair. During that time, we also learned that the most likely culprit of ischemic colitis during EVAR is distal embolization, hypotension, and shock. [10] [11] [12] Dr Farivar and colleagues ought to be congratulated for a detailed analysis of the data "available within the NSQIP," whereby they performed a stepwise univariate analysis examining the relationships between each "preoperative and intraoperative variable and significant postoperative complications and mortality" and developed a multivariable logistic regression model for each of the identifiable significant postoperative complications. In doing so, they concluded that hypogastric artery interruption with EVAR is associated with longer and more complicated hospital stay, increased risk for ischemic colitis, and increased risk for renal failure requiring dialysis. The overarching message here is that compared with infrarenal abdominal aortic aneurysm only, EVAR for more complex aortoiliac aneurysms requires further interventions, such as hypogastric artery embolization that is likely to be associated with prolonged operative times, increased use of contrast agents, increased blood loss, and the resultant increased morbidity.
This manuscript has several limitations in that it falls short in identifying some critical data analysis that is needed for us to better understand how to best optimize outcomes when performing concomitant hypogastric artery interruption during EVAR. This also highlights some of the fundamental issues in dealing with and interpreting large national databases such as the NSQIP, which unfortunately could not capture variables such as (1) unilateral vs bilateral hypogastric artery embolization; (2) staged hypogastric artery embolization vs not; (3) technique for unilateral vs bilateral hypogastric artery embolization with preservation of pelvic branches (use of coils vs Amplatzer vascular plugs), which is essential for preserving pelvic-mesenteric collaterals and avoiding ischemic colitis; (4) pre-existing superior mesenteric artery or inferior mesenteric artery occlusive disease that would increase risk for development of ischemic colitis; (5) interruption of ipsilateral iliac and femoral circumflex collateral arteries during femoral artery cutdown; (6) performing sigmoidoscopy for diagnosis of ischemic colitis vs clinical judgment only; and (7) many of the variables that we optimize when performing EVAR, such as identifying patients with pre-existing chronic renal insufficiency and optimizing contrast material load, eliminating nephrotoxic drugs, planning preoperative hydration, and treating concomitant critical renal artery stenosis when needed. 13 I applaud the authors for highlighting some of these limitations in the manuscript. This study highlights how even the largest nationally validated NSQIP database has significant limitations and prevents us from drawing meaningful conclusions. Under such circumstances, it is our personal biases that are highlighted in our interpretations and conclusions.
I am honored to provide this commentary and want to thank the Journal of Vascular Surgery editors for the privilege.
